January 27, 2023
Daiichi Sankyo and AstraZeneca said on January 26 that their antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) is now approved in Europe for HER2 low metastatic breast cancer. This triggers a milestone payment of US$150 million from the UK firm...read more